Cohance Lifesciences Ltd

AI
Cohance Life Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Cohance Lifesciences Ltd

₹ 457 -0.92%
04 Sep - close price
cohance.com BSE: 543064 NSE: COHANCE
About

Cohance Lifesciences is a Hyderabad-based CDMO operating across pharmaceutical development, manufacturing, APIs, formulations and specialty chemicals. The company states that it features among the Top 20 CDMOs globally; its Pharma CDMO business works with 19 of the top 20 global innovators, while the API portfolio ranks among the top three suppliers in 8 of its top 10 molecules.[1][2]

Key Points

Rebranding:
Cohance Lifesciences Limited is the new identity of erstwhile Suven Pharmaceuticals Limited. In 2025, the group consolidated its CDMO capabilities under the Cohance Lifesciences.

Website BSE NSE
  • Market Cap ₹ 17,469 Cr.
  • Current Price ₹ 457
  • High / Low ₹ 1,039 / 267
  • Stock P/E 162
  • Book Value ₹ 102
  • Dividend Yield 0.00 %
  • ROCE 5.81 %
  • ROE 4.89 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 10.6% over last 3 years.
  • Promoters have pledged 94.6% of their holding.
  • Debtor days have increased from 88.0 to 110 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of Nifty Smallcap 50 BSE 400 MidSmallCap Index Nifty Smallcap 500 Nifty500 Healthcare Nifty Smallcap 250

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
348 231 220 253 488 604 676 840 549 556 545 619 422
181 133 154 180 363 398 439 611 437 435 449 520 421
Operating Profit 167 98 66 73 125 205 237 229 112 121 95 99 1
OPM % 48% 42% 30% 29% 26% 34% 35% 27% 20% 22% 18% 16% 0.3%
11 20 14 17 19 16 22 -4 6 16 1 -18 12
Interest 1 0 2 2 10 10 11 10 10 9 9 9 7
Depreciation 13 12 13 17 31 38 44 54 45 44 47 51 50
Profit before tax 164 105 65 71 103 174 205 161 63 84 41 20 -43
Tax % 26% 25% 29% 25% 27% 21% 25% 27% 26% 21% 29% 58% 5%
121 80 47 53 75 138 153 117 46 66 29 8 -45
EPS in Rs 4.74 3.13 1.84 2.10 2.96 5.44 6.01 4.73 1.28 1.94 0.96 0.51 -0.63
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
378 834 1,010 1,320 1,340 1,051 2,608 2,269 2,142
206 449 567 738 766 645 1,811 1,841 1,825
Operating Profit 172 385 443 582 574 406 797 427 316
OPM % 45% 46% 44% 44% 43% 39% 31% 19% 15%
1 66 68 133 46 62 53 4 11
Interest 3 23 12 9 13 7 41 37 34
Depreciation 12 24 32 39 48 55 167 187 192
Profit before tax 158 405 468 668 560 406 643 207 101
Tax % 31% 22% 23% 32% 27% 26% 25% 27%
109 317 362 454 411 300 484 150 59
EPS in Rs 12.45 14.23 17.83 16.16 11.80 19.14 4.68 2.78
Dividend Payout % 0% 20% 14% 28% 37% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 18%
3 Years: 19%
TTM: -20%
Compounded Profit Growth
10 Years: %
5 Years: -12%
3 Years: -23%
TTM: -77%
Stock Price CAGR
10 Years: %
5 Years: -3%
3 Years: -4%
1 Year: -51%
Return on Equity
10 Years: %
5 Years: 15%
3 Years: 11%
Last Year: 5%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 0.00 13 25 25 25 25 25 38
Reserves 578 832 1,155 1,502 1,710 2,025 3,623 3,873
83 186 143 97 70 65 486 400
123 142 151 205 160 138 1,346 1,415
Total Liabilities 783 1,173 1,474 1,830 1,966 2,254 5,480 5,727
271 357 441 534 663 670 3,107 3,369
CWIP 111 102 96 30 165 179 334 178
Investments 7 338 542 598 536 904 337 529
394 376 395 667 601 501 1,702 1,652
Total Assets 783 1,173 1,474 1,830 1,966 2,254 5,480 5,727

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
50 407 383 330 457 358 673 368
-65 -413 -311 -136 -195 -362 -388 -251
26 7 -76 -156 -242 -14 -327 -165
Net Cash Flow 11 1 -5 37 20 -18 -42 -48
Free Cash Flow -6 304 272 255 171 307 357 169
CFO/OP 49% 128% 111% 88% 105% 115% 107% 102%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 142 51 37 65 30 46 108 110
Inventory Days 556 278 243 259 279 268 209 310
Days Payable 190 113 100 97 63 49 120 157
Cash Conversion Cycle 509 217 180 228 247 265 197 263
Working Capital Days 205 64 56 108 99 115 106 133
ROCE % 50% 40% 41% 32% 19% 21% 6%

Insights

In beta
Nov 2023 Mar 2025 Mar 2026
Commercial Patented Molecules (Pharma CDMO)
count

Log in to view insights

Please log in to see hidden values.

Login
Phase III Pipeline Molecules (Pharma CDMO)
count
R&D Scientists
count
Top 3 Position in API Portfolio (out of top molecules)
count
Niche Technology Revenue Share (ADC, Oligo, Peptides)
% of revenue
Phase III Pipeline Intermediates (Pharma CDMO)
count
USFDA / Regulatory Audited Manufacturing Sites
count
API+ DMF / CEP Filings (Annual)
count
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

1 Recently
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
60.00% 60.00% 50.10% 50.10% 50.10% 50.10% 50.10% 66.41% 57.49% 57.49% 57.49% 57.49%
10.01% 10.14% 9.54% 9.80% 10.70% 10.84% 11.05% 7.23% 6.51% 6.01% 5.59% 6.50%
14.13% 15.94% 17.24% 17.42% 16.95% 16.67% 16.60% 11.40% 20.81% 21.57% 21.79% 20.09%
0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
15.85% 13.93% 23.11% 22.67% 22.26% 22.37% 22.24% 14.95% 15.16% 14.91% 15.11% 15.92%
No. of Shareholders 73,71570,05268,93265,77769,33784,21086,32580,91075,28481,87785,23099,149

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls